

Notification HUM-6787, 6789, 6792, 6792, 6795, 6797, 6799, 6801:

Category

HCPCS - Drugs & Biologicals

Topic

HCPCS J9196 and J9201 – Gemcitabine HCl, 200 mg

What is changing? / Change Description:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Description</u>
<u>6787</u>	<u>Gemcitabine HCl, 200 mg</u>	<u>For provider specialties other than home infusion therapy or pharmacy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 11 units per date of service if submitted with one of the following diagnoses:• Gestational trophoblastic neoplasia • Nodular lymphocyte-predominant Hodgkin's lymphoma</u>
<u>6789</u>	<u>Gemcitabine HCl, 200 mg</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 1 visit every 3 days if submitted with one of the following diagnoses:• Hodgkin's lymphoma (classical)• Kidney cancer• Nodular lymphocyte-predominant Hodgkin's lymphoma</u>
<u>6792</u>	<u>Gemcitabine HCl, 200 mg</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 1 visit every 4 days if submitted with a diagnosis of non-small cell lung cancer.</u>
<u>6795</u>	<u>Gemcitabine HCl, 200 mg</u> <u>Codes J9196 & J9201</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 5 visits every 6 weeks if submitted with one of the following diagnoses: • Ampullary adenocarcinoma• B-cell lymphoma• Breast cancer• Cervical cancer• Hodgkin's lymphoma (classical)• Non-small cell lung cancer• Occult primary• Ovarian cancer• Peritoneal mesothelioma• Pleural mesothelioma• Small bowel adenocarcinoma• Small cell lung cancer• Soft tissue sarcoma• T-cell lymphoma• Testicular cancer• Urothelial carcinoma• Uterine sarcoma</u>



<u>6797</u>	<u>Gemcitabine HCl, 200 mg</u> <u>Codes J9196 & J9201</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 6 visits every 6 weeks if submitted with a diagnosis of kidney cancer.</u>
<u>6799</u>	<u>Gemcitabine HCl, 200 mg</u> <u>Codes J9196 & J9201</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS codes J9196 or J9201 to no more than 8 visits every 26 weeks if submitted with a diagnosis of nodular lymphocyte-predominant Hodgkin's lymphoma.</u>
<u>6801</u>	<u>Gemcitabine HCl, 200 mg</u> <u>Codes J9196 & J9201</u>	<u>We do not reimbursement charges for HCPCS codes J9196 or J9201 if the patient is under 18 and the diagnosis on the claim is nodular lymphocyte-predominant Hodgkin's lymphoma.</u>

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change? / Change Reason:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Reason</u>
<u>6787</u>	<u>Gemcitabine HCl, 200 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia. Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>

6789	<u>Gemcitabine HCl, 200 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u> <u>Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
6792	<u>Gemcitabine HCl, 200 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u> <u>Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
6795	<u>Gemcitabine HCl, 200 mg</u> <u>Codes J9196 & J9201</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u> <u>Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>

<u>6797</u>	<u>Gemcitabine HCl, 200 mg Codes J9196 & J9201</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u> <u>Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
<u>6799</u>	<u>Gemcitabine HCl, 200 mg Codes J9196 & J9201</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>
<u>6801</u>	<u>Gemcitabine HCl, 200 mg Codes J9196 & J9201</u>	<u>According to the FDA-approved package insert and prescribing information and the pharmaceutical compendia, the safety and effectiveness of gemcitabine HCl have not been established for patients under 18 for the indications above.</u>